Cellular histamine in blood and bone marrow has been identified histochemically using an o-phthaldialdehyde fluorescence reaction. The specificity of the reaction was tested by a spectrofluorometric analysis of cell extracts. In normal blood, the basophils emit a bright yellow fluorescence, whereas neutrophils, eosinophils and platelets react less consistently and when they do, they give off a less intense yellow or blue emission. In normal marrow, basophils react strongly whereas the metamyelocytes and later granular cells show only a weak yellow or blue fluorescence. In chronic myeloid leukaemia, cells of the granular series emit a strong yellow fluorescence at all stages of development, although still less intense than the basophils. During remission, the fluorescence pattern of cells from leukaemic subjects reverts to that of normal cells.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/BF01003626 | DOI Listing |
Acta Med Indones
October 2024
Department of Internal Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia.
This report describes a rare case of anuric acute kidney injury related to suspected urate nephropathy in a 23-year-old male with chronic phase of Chronic Myeloid Leukemia (CML). The patient presented with anuria and limb edema, with a history of imatinib-treated CML. Investigations revealed probable urate crystals causing bilateral hydronephrosis and hydroureters.
View Article and Find Full Text PDFSemin Immunopathol
January 2025
Institute for Clinical Chemistry and Laboratory Medicine, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Fetscherstrasse 74, 01307, Dresden, Germany.
Metabolic flexibility is key for the function of myeloid cells. Arginine metabolism is integral to the regulation of myeloid cell responses. Nitric oxide (NO) production from arginine is vital for the antimicrobial and pro-inflammatory responses.
View Article and Find Full Text PDFClin Lymphoma Myeloma Leuk
December 2024
Clinica IMAT Oncomedica Auna S.A.S, Montería, Colombia.
Background: Chronic myeloid leukemia (CML) treatment has significantly evolved with the introduction of tyrosine kinase inhibitors. However, access to these treatments and outcomes vary globally. This study examines 2 decades of CML management in Colombia using the RENEHOC registry, focusing on TKI efficacy, safety, and healthcare system challenges.
View Article and Find Full Text PDFJ Mol Diagn
January 2025
Department of Pediatrics and Adolescent Medicine, University Hospital Erlangen, Erlangen, Germany; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany; Bavarian Cancer Research Center (BZKF), Erlangen, Germany. Electronic address:
Achieving a stable deep molecular response with the option to discontinue tyrosine kinase inhibitors (TKI) treatment is the new therapeutic goal for patients with chronic myeloid leukemia (CML). Several studies have shown that individuals expressing the BCR::ABL1 e14a2 transcript achieve a major molecular response more rapidly than those with the e13a2 transcript. However, technical issues may have confounded these observations, and data for pediatric patients are limited.
View Article and Find Full Text PDFImmunity
January 2025
Laboratory of Myeloid Cell Biology in Tissue Damage and Inflammation, VIB-UGent Center for Inflammation Research, Technologiepark-Zwijnaarde 71, Ghent 9052, Belgium; Department of Biomedical Molecular Biology, Faculty of Science, Ghent University, Ghent, Belgium. Electronic address:
Our understanding of the functional heterogeneity of resident versus recruited macrophages in the diseased liver is limited. A population of recruited lipid-associated macrophages (LAMs) has been reported to populate the diseased liver alongside resident Kupffer cells (KCs). However, the precise roles of these distinct macrophage subsets remain elusive.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!